IntelliPharmaCeutics International (TSXV:IPCI) YoY EBITDA Growth : -914.29% (As of Aug. 2023)

View and export this data going back to 1999. Start your Free Trial

What is IntelliPharmaCeutics International YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. IntelliPharmaCeutics International's YoY EBITDA Growth for the quarter that ended in Aug. 2023 was -914.29%.

IntelliPharmaCeutics International's EBITDA per Share for the three months ended in Aug. 2023 was C$-0.07.

IntelliPharmaCeutics International YoY EBITDA Growth Historical Data

The historical data trend for IntelliPharmaCeutics International's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IntelliPharmaCeutics International YoY EBITDA Growth Chart

IntelliPharmaCeutics International Annual Data

Trend

Nov13

Nov14

Nov15

Nov16

Nov17

Nov18

Nov19

Nov20

Nov21

Nov22

YoY EBITDA Growth

Get a 7-Day Free Trial

-9.14

87.40

75.78

-74.31

48.95

IntelliPharmaCeutics International Quarterly Data
	Nov18	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23
YoY EBITDA Growth	Get a 7-Day Free Trial															81.58	69.57	60.71	107.14	-914.29

IntelliPharmaCeutics International YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

IntelliPharmaCeutics International's YoY EBITDA Growth for the fiscal year that ended in Nov. 2022 is calculated as:

	YoY EBITDA Growth (A: Nov. 2022 )
=	(EBITDA per Share (A: Nov. 2022 )	-	EBITDA per Share (A: Nov. 2021 ))	/	\| EBITDA per Share (A: Nov. 2021 ) \|
=	(-0.097	-	-0.19)	/	\| -0.19 \|
=	48.95 %

IntelliPharmaCeutics International's YoY EBITDA Growth for the quarter that ended in Aug. 2023 is calculated as:

	YoY EBITDA Growth (Q: Aug. 2023 )
=	(EBITDA per Share (Q: Aug. 2023 )	-	EBITDA per Share (Q: Aug. 2022 ))	/	\| EBITDA per Share (Q: Aug. 2022 )) \|
=	(-0.071	-	-0.007)	/	\| -0.007 \|
=	-914.29 %

IntelliPharmaCeutics International YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of IntelliPharmaCeutics International's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

IntelliPharmaCeutics International (TSXV:IPCI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IntelliPharmaCeutics International Inc (TSXV:IPCI) » Definitions » YoY EBITDA Growth

Comparable Companies

Traded in Other Exchanges

IPCIF:USA I4AA:Germany

Address

30 Worcester Road, Toronto, ON, CAN, M9W 5X2

Website

https://www.intellipharmaceutics.com

IntelliPharmaCeutics International Inc is a pharmaceutical company. The company is engaged in the research, development, and manufacturing of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to the development of a range of existing and new pharmaceuticals. Its ongoing drug development programs are at various stages of development in therapeutic areas that include neurology, cardiovascular, GIT, and pain. The company's product, a generic of Focalin XR, is partnered with Par Pharmaceutical, Inc. and received FDA approval. It derives revenue from the United States.

IntelliPharmaCeutics International (TSXV:IPCI) Headlines

No Headlines